Medicago Shut Down: COVID-19 Vaccine Competition Among Reasons

$364m Impairment Loss For Mitsubishi

Medicago had been facing several challenges with its COVID-19 vaccine COVIFENZ
Medicago faced multiple challenges for lead vaccine Covifenz • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip